Tuesday, July 19, 2016

SciClone Abandons Acquisition Hopes

Foster City-based SciClone Pharmaceuticals said this morning that it has decided to remain an independent, publicly traded company, and is no longer talking to potential acquirers. The company--which is traded on the NASDAQ as SCLN--had launched a "strategic review" of its business in February, which was being run by Lazard. The company said that, after approaching a "significant number" of potential acquirers, it has instead decided to remain an independent, publicly traded company. The company's lead product is ZADAXIN (thymalfasin), which is used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers.